



Right Place  
Right Strain  
**Right Protection**

It's about precision.

---

# **VAKSIMUNE** **IB NV-2**

PROTECTION AGAINST  
INFECTIOUS BRONCHITIS  
VARIANT 2



# VAKSIMUNE® IB NV-2

## Challenges & Our Commitment:

Infectious Bronchitis Virus (IBV) continues to threaten poultry production globally due to its rapid mutation and emergence of region-specific variants. The GI-23 genotype (Variant 2), first identified in Israel, now dominates in the Middle East and parts of Asia. Genetically distinct from classical and QX-like strains, GI-23 reduces the effectiveness of conventional vaccines and is linked to severe respiratory disease, kidney damage, increased mortality, and poor flock performance (Finger et al., 2024), (Zanaty et al., 2016).

Vaksindo addresses this challenge with Vaksimune IB NV-2, a vaccine developed from a GI-23 strain. Specifically tailored for the region, it offers precise protection where traditional options fall short helping poultry producers safeguard flock health with greater confidence.

## Features:

VAKSIMUNE® IB NV-2 is a freeze dried live vaccine virus, each dose contains :

**IB BVN 005 (Var 2) virus > 10<sup>8.9</sup> EID<sub>50</sub>**

VAKSIMUNE® IB NV-2 (BVN 005) strain has been specifically developed to protect broiler, breeder, and layer chickens against infectious bronchitis caused by the GI-23 (Variant 2) strain. It is particularly effective in reducing mortality and performance losses associated with nephropathogenic infections in broilers, while also supporting overall flock health in breeders and layers.



## Vaccination Strategy

1st Vaccination : Day One  
2nd Vaccination : 5 Week

## Vaccine Administration :

Vaccine can be administered via different routes of eye drop and spray

## Packing size:

Available in 500, 1000 & 2000 Doses

## VAKSIMUNE® IB NV-2 Benefit



### Protection against Nephropathic lesion

VAKSIMUNE® IB NV-2 helps protect chickens from kidney lesions commonly associated with GI-23 infection, especially in broilers where nephropathogenic IB can cause mortality and performance loss.




### Improved Growth and Performance in Broilers

By minimizing kidney damage and reducing systemic impact, VAKSIMUNE® IB NV-2 helps maintain weight gain and feed conversion.




### Targeted Protection for the Middle East

Formulated with IB Variant 2 (GI-23) strain, VAKSIMUNE® IB NV-2 is developed to match the dominant regional challenge in the Middle East.



### Neutralization Index Confirms Protective Immunity

Layer chickens vaccinated with NV-2 on days 4 and 35 showed rising neutralization index (NI) values, reaching 3.6 by day 49, while unvaccinated controls remained at 0.4. An NI  $\geq 2.0$  is considered protective, confirming that NV-2 induces a strong and lasting immune response. Since the NI test is strain-specific, these results reflect protection specifically against IBV Variant 2.



### Tracheal Lesion Scores After Challenge

Birds were vaccinated on day 1 and 14, challenged with Variant 2 IBV on day 28, and tracheas were examined on day 33. The NV-2:NV-2 group showed the lowest lesion score (0.86), indicating strong protection, while 793B:793B and Ma5:793B showed higher damage (2.43 and 2.29). Ciliostasis was scored in 10 tracheal rings per bird using a 0-4 scale: 0 = 100% motile cilia, 1 = 75-100%, 2 = 50-75%, 3 = 25-50%, and 4 = less than 25%. Lower scores reflect healthier airways and better vaccine performance.